About Celfex

Our Company

Celfex AB is a Swedish biopharmaceutical company based in Goteborg, and a subsidiary of MHG Management GmbH. We are dedicated to developing innovative dermatological treatments that address the unmet needs of patients suffering from Atopic Dermatitis (Eczema).

Our focus is on the development of a proprietary topical Fexofenadine formulation, which has shown promising multi-action potential in treating mild to moderate eczema in both children and adults.

Our Mission

Our passion is to bring dermatology solutions to market which help to relieve children and adults suffering from mild to medium Eczema (Atopic Dermatitis). We believe that innovative approaches to well-known molecules can unlock new therapeutic potential.

Intellectual Property

Celfex AB holds sub-licensed IP from MHG Management GmbH covering the topical application of Fexofenadine for the treatment of Atopic Dermatitis. This IP portfolio includes patents and patent applications protecting our novel formulation and its therapeutic applications.

Our Parent Company

Celfex AB is a subsidiary of MHG Management GmbH, a diversified management and investment company. MHG provides strategic oversight and resources to support Celfex's clinical development programs and commercialization efforts.